Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240902 · ClinicalTrials.gov registry record · NA
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement
A NA study, sponsored by Medtronic Cardiovascular.
- Completed
- Registry status
- NA
- Development phase
- 1,453
- Enrollment target
NCT01240902 is a NA study that has completed, run by Medtronic Cardiovascular. The registered enrollment target is 1,453 participants.
The verdict
NCT01240902, a NA study, has completed, sponsored by Medtronic Cardiovascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,453 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted high risk for aortic valve surgery and/or very high risk for aortic valve surgery.
Interventions
- DEVICE Surgical Aortic Valve Replacement (SAVR)
- DEVICE Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,453 participants |
| Start Date | 2010-12-10 |
| Est. Completion | 2019-05-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01240902
The ClinicalTrials.gov registry entry for NCT01240902 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,453 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgical Aortic Valve Replacement (SAVR) is the first listed.
NCT01240902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01240902 about?
NCT01240902 is a clinical study titled "Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement". The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted high risk for aortic valve surgery and/or very high risk for aortic valve surgery.
What is the current status of trial NCT01240902?
This trial is currently completed. It is a NA study. The enrollment target is 1,453 participants. The study started on 2010-12-10. Estimated completion is 2019-05-15.
What interventions are being tested in trial NCT01240902?
The interventions under investigation include: Surgical Aortic Valve Replacement (SAVR) (DEVICE), Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI) (DEVICE).
Who is sponsoring clinical trial NCT01240902?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.